LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab Our Logo
Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost CI
Just when you think you've got it all figured out... Our Logo
Illumina Board Approves Grail Spin-Off; New Company to List on Nasdaq MT
Illumina to spin off Grail in June RE
A rate cut is finally in sight Our Logo
Illumina, Inc. Announces Executive Changes CI
Jefferies Initiates Illumina With Hold Rating, $115 Price Target MT
ANALYSTS RECOMMENDATIONS : Best Buy, Dell Technologies, Moderna, AMD, National Grid... Our Logo
Illumina, Inc. Seeks M&A CI
Transcript : Illumina, Inc. Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 09:00 AM
Declaration of Voting Results by Illumina Inc CI
Illumina, Inc. Appoints Anna Richo to its Board of Directors CI
Daiwa Securities Adjusts Price Target on Illumina to $120 From $133 MT
Transcript : Illumina, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08:30 AM
Transcript : Illumina, Inc. - Analyst/Investor Day
Illumina Files Registration Statement for Planned GRAIL Divestiture MT
Bernstein Adjusts Illumina's Price Target to $130 From $129 MT
TD Cowen Adjusts Illumina's Price Target to $140 From $150 MT
Baird Raises Price Target on Illumina to $128 From $125 MT
Evercore ISI Adjusts Price Target on Illumina to $195 From $200 MT
Leerink Adjusts Price Target on Illumina to $150 From $155 MT
Illumina reaffirms annual revenue forecast over continued sluggish demand RE
Illumina Q1 Non-GAAP Earnings Increase, Revenue Decreases -- Shares Down After Hours MT
Transcript : Illumina, Inc., Q1 2024 Earnings Call, May 02, 2024
Chart Illumina, Inc.
More charts
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
103.4 USD
Average target price
155.5 USD
Spread / Average Target
+50.44%
Consensus
  1. Stock Market
  2. Equities
  3. ILMN Stock
  4. News Illumina, Inc.
  5. Illumina : Appoints Bob Ragusa as GRAIL's CEO
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW